It was developed back in 2012, as a treatment for people with type 2 diabetes, but it took almost 5 years before it was FDA-approved for use
Never Share a WEGOVY FlexTouch Pen Between Patients Advise patients that they must never share a WEGOVY FlexTouch with another person, even if the needle is changed, because doing so carries a risk for transmission of blood-borne pathogens [see Warnings and Precautions (5.11)]
For weight loss specifically, it is generally prescribed only when there is a qualifying reason, such as diabetes or pre-diabetes
Also, these products are free from GMO, gluten and artificial additives, thereby adding a solid layer of customer safety
Dihexa peptide is primarily being studied for its ability to enhance cognitive function and support nerve regeneration